Began Therapeutics' base editing technology allows for precise conversion of DNA letters to different levels. The company's most advanced program involves the treatment of sickle-eyed patients for up to 20 months. The most recent example of this technique was achieved when a baby born with a rare metabolic disorder was given a personalized treatment.